b-blockers in heart failure with low EF

BMJ did a recent meta-anal of b-blockers in pts with chf with decreased ejection fraction. 21 studies with 23K pts, median age 61, 77% men, median LVEF 25%, analyzing data on different b-blockers (most studies with carvedilol), followed median 12 months, assessing primary endpoint of all-cause death (see chf bblockers reduced EF metaanal bmj 2013 in dropbox). overall conclusion  was that there was not much difference between the many b-blockers analyzed (carvedilol, atenolol, metoprolol, bucindilol, bisoprolol or nebivolol), with average RR 0.69 (ie, 31% reduction). a few points:

--generic b-blockers (eg carvedilol, metoprolol, bisoprolol) have the best data ( there was only one study with atenolol, though it was not statistically significant different from any of the ones tested)
--carvedilol had the best (not statistically significant) decrease in mortality (40%) with absolute risk reduction of 6.6%. perhaps attrib to its effects as antioxidant, improving endothelial function, decreased effects on glycemic control in diabetics related to its increase in insulin sensitivity and decrease in microalbinurea).  but it is BID, which is hard for some patients.
--similar effects on improving LVEF (though bucindolol was a little better)
--similar discontinuation rates (though carvedilol was a little better tolerated, esp in the recent COMET trial)

so, mortality benefit of b-blockers seems to be a class effect. my own bias is to use carvedilol, since it has the best data and a trend to better outcomes, though it is a BID drug and requires a pretty slow titration up. But if someone is already on another b-blocker (eg atenolol) and tolerating it well, i would be hesitant to change the regimen given the lack of firm data against any of the above b-blockers and my prior experiences of being unsuccessful in making drug transitions (pt not tolerate the new drug, getting confused about meds/med changes, requiring more frequent clinic visits to assess tolerance and efficacy, etc)


Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

opioidsx3, and drug company shenanigans to boot

This is a triple blog on a few recent developments in the opioid world. 1. The FDA just announced that they are seeking removal of  Opana  ER, long-acting  oxymorphone  hydrochloride, "based on its concern that the benefits of the drug may no longer outweigh its risks". [And certainly many of us thought it was ridiculous to approve it from the start. We have all been through this scene before with  oxycontin ...].  The FDA found (not so surprisingly) that there was a shift in its route of abuse from nasal to injection after the product was reformulated (it had been reformulated "to make it more resistant to physical and chemical manipulation for abuse by snorting or injecting"....).   This increase in injection use has been associated with outbreaks of HIV, hepatitis C and some cases of thrombotic  microangiopathy . And if the company refuses to remove the drug from the market voluntarily, the FDA will forma...
Read more

getting rid of vaccines?????

  --as we quickly approach the post-science darkening ages, i thought it would be useful to recirculate an old blog on measles. But first, some comments on the anti-vaxxers and polio:       -- per the NY Times: "The lawyer helping Robert F. Kennedy Jr. pick federal health officials for the incoming Trump administration has petitioned the government to revoke its approval of the polio vaccine, which for decades has protected millions of people  from a virus that can cause paralysis or death…that campaign is just one front in the war that the lawyer, Aaron Siri, is waging against vaccines of all kinds ”: https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html       --it is abundantly clear that the polio epidemic in the US in the 1950s led to both lots of morbidity and mortality back then, that lots of post-polio muscular problems until now, that the vaccine invented then by Jonas Salk dramatically stemmed the virus...
Read more